Golembesky AK - Search Results

1

Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study.

Chase DM, Hanna M, Lim JT, Boyle TAC, Guinter M, Richey M, Patel K, Schilder JM, Hurteau JA, Golembesky AK. Chase DM, et al. Among authors: golembesky ak. Oncol Ther. 2025 Jan 7. doi: 10.1007/s40487-024-00318-y. Online ahead of print. Oncol Ther. 2025. PMID: 39776033 Free article.

2

Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA.

Lim J, Samuelsen C, Golembesky A, Shrestha S, Wang L, Griebsch I. Lim J, et al. Future Oncol. 2019 May;15(13):1493-1504. doi: 10.2217/fon-2019-0052. Epub 2019 Mar 19. Future Oncol. 2019. PMID: 30888202 Free article.

3

Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.

Samuelsen C, Lim J, Golembesky A, Shrestha S, Wang L, Griebsch I. Samuelsen C, et al. J Med Econ. 2020 Jan;23(1):48-53. doi: 10.1080/13696998.2019.1645681. Epub 2019 Aug 9. J Med Econ. 2020. PMID: 31314630 Free article.

4

Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance.

Chase D, Perhanidis J, Gupta D, Kalilani L, Golembesky A, González-Martín A. Chase D, et al. Oncol Ther. 2023 Jun;11(2):245-261. doi: 10.1007/s40487-023-00227-6. Epub 2023 Apr 4. Oncol Ther. 2023. PMID: 37016186 Free PMC article.

5

Association of Multiple High-Risk Factors on Observed Outcomes in Real-World Patients With Advanced Ovarian Cancer Treated With First-Line Therapy.

Chase D, Perhanidis J, Gupta D, Kalilani L, Golembesky A, González-Martín A. Chase D, et al. JCO Clin Cancer Inform. 2023 Jun;7:e2200189. doi: 10.1200/CCI.22.00189. JCO Clin Cancer Inform. 2023. PMID: 37294913 Free PMC article.

6

Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study.

Rimel B, Boyle TAC, Burns S, Lim J, Hartman J, Kalilani L, Schilder JM, Hurteau JA, Golembesky A. Rimel B, et al. Oncol Ther. 2024 Sep;12(3):465-475. doi: 10.1007/s40487-024-00281-8. Epub 2024 Jul 4. Oncol Ther. 2024. PMID: 38965204 Free PMC article.

7

Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study.

Thaker PH, Areli Calderón Boyle T, Burns S, Lim J, Hartman J, Kalilani LV, Schilder JM, Hurteau JA, Golembesky AK. Thaker PH, et al. Among authors: golembesky ak. Int J Gynecol Cancer. 2024 Dec 2;34(12):1924-1931. doi: 10.1136/ijgc-2024-005611. Int J Gynecol Cancer. 2024. PMID: 39244209 Free PMC article.

8

Real-world overall survival in second-line maintenance niraparib monotherapy versus active surveillance in patients with BRCA wild-type recurrent ovarian cancer.

Coleman RL, Perhanidis JA, Kalilani L, Zimmerman NM, Golembesky A, Moore KN. Coleman RL, et al. Ther Adv Med Oncol. 2024 Nov 14;16:17588359241292272. doi: 10.1177/17588359241292272. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39552638 Free PMC article.

9

Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer.

Salani R, Calderón Boyle TA, Lim J, Schilder JM, Hurteau JA, Perhanidis J, Golembesky A, Backes FJ. Salani R, et al. Future Oncol. 2025 Jan 17:1-7. doi: 10.1080/14796694.2024.2441654. Online ahead of print. Future Oncol. 2025. PMID: 39819260 Free article.

10

Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists.

Strober B, Kotowsky N, Medeiros R, Mackey RH, Harrold LR, Valdecantos WC, Flack M, Golembesky AK, Lebwohl M. Strober B, et al. Among authors: golembesky ak. Dermatol Ther (Heidelb). 2021 Apr;11(2):529-541. doi: 10.1007/s13555-021-00493-0. Epub 2021 Feb 27. Dermatol Ther (Heidelb). 2021. PMID: 33638115 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters